Head-and-neck squamous cell carcinoma carcinoma (HNSCC) is a disease where the prognosis varies substantially between patients. Human papilloma virus (HPV) positive oropharyngeal carcinoma is, in relative terms, a favorable subtype with a 3-year overall survival (OS) of around 80% [1]. It has been suggested that treatment de-intensification would be possible in this group without compromising the treatment effect, and several such studies are ongoing [2]. This begs the question whether we can identify subset of HPV positive patients where de-intensification may be detrimental for long term survival due to a – for the group – unfavorable disease characteristics.
from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2A1KD0h
via IFTTT
Ιατρική Αλέξανδρος Γ. Σφακιανάκης,Αναπαύσεως 5 Άγιος Νικόλαος 72100 Κρήτη 00302841026182 Medical Articles by Alexandros G.Sfakianakis PhD,Anapafseos 5 Agios Nikolaos 72100 Crete Greece 00306932607174
! # Ola via Alexandros G.Sfakianakis on Inoreader
Πέμπτη 2 Νοεμβρίου 2017
A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου